✦ LIBER ✦

Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line

✍ Scribed by Young Sook Son; Jae Myoung Suh; Soo Hyun Ahn; Jun Chul Kim; Jae Youn Yi; I. K. Chung; K. C. Hur; Weon-Seon Hong; Mark T. Muller

Publisher: Springer
Year: 1998
Tongue: English
Weight: 688 KB
Volume: 41
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050751

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Decreased levels of topoisomerase IIα in

Decreased levels of topoisomerase IIα in human renal cell carcinoma lines resistant to etoposide

✍ Johan M. W. Scheltema; Johan C. Romijn; Gert J. van Steenbrugge; William T. Beck 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 326 KB

Lack of cross-resistance to fostriecin i

Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance

✍ Steven Jong; Jan G. Zijlstra; Nanno H. Mulder; Elisabeth G. E. Vries 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 425 KB

A lack of detectable modification of top

A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance

✍ Bridget T. Hill; Richard D. H. Whelan; Louise K. Hosking; Sharon A. Shellard; Mi 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 471 KB

## Abstract Etoposide (VP‐16) resistance is expressed following __in vitro__ exposure of HN‐1 and MCF‐7 human tumor cells to the drug itself or to fractionated × irradiation. VP‐16‐selected sublines prove cross‐resistant to Adriamycin, amsacrine and actinomycin D, whilst X‐ray‐pretreated sublines s

Oestrogen potentiates topoisomerase-II-m

Oestrogen potentiates topoisomerase-II-mediated cytotoxicity in an activated subpopulation of human breast cancer cells: Implications for cytotoxic drug resistance in solid tumours

✍ R. J. Epstein; P. J. Smith; J. V. Watson; C. Waters; N. M. Bleehen 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 811 KB

Primary resistance to chemotherapeutic agents is a major problem in the management of advanced cancer. By using oestrogen to modulate the topoisomerase II content of T-47D human breast cancer cells, we show here that cell subpopulations resistant to the topoisomerase-ll-interactive drug VP 16 (etopo

Identification of chromosomal loci assoc

Identification of chromosomal loci associated with non-P-glycoprotein–mediated multidrug resistance to topoisomerase II inhibitor in lung adenocarcinoma cell line by comparative genomic hybridization

✍ Stéphanie Struski; Martine Doco-Fenzy; Aurélie Trussardi; Linda Masson; Nadine G 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB 👁 2 views

Effects of wild-type p53 expression on t

Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines

✍ Daniel Hochhauser; Nikola I. Valkov; Jana L. Gump; Irene Wei; Carolyn O'Hare; Jo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

The p53 null HL-60 cell line was transfected with plasmids coding for either the wild-type p53 or mutant p53 gene. The stable expression of wild-type p53 resulted in a significant increase in sensitivity to the topoisomerase II poisons etoposide and doxorubicin, but not to the topoisomerase II inhib